• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Endo Pharmaceutical Holdings

Endo Pharmaceutical Holdings

Endo International PLC ENDP

Last Price$15.38Day Change (%)1.05%
Open Price$15.72Day Change ($)0.16
Day Range15.36–16.0552-Week Range12.56–88.54

As of Fri 5/27/2016 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Endo International plc and Advises Investors to Contact the Firm

    IMPORTANT INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims Against Endo International plc and Advises Investors to Contact the Firm

  2. UPDATE: How investors can profit from 'funny' corporate accounting

    UPDATE: How investors can profit from 'funny' corporate accounting

  3. UPDATE: How investors can profit from 'funny' corporate accounting

    UPDATE: How investors can profit from 'funny' corporate accounting

  4. UPDATE: How investors can profit from 'funny' corporate accounting

    UPDATE: How investors can profit from 'funny' corporate accounting

  5. UPDATE: How investors can avoid getting hoodwinked and use 'funny' corporate accounting to their advantage

    UPDATE: How investors can avoid getting hoodwinked and use 'funny' corporate accounting to their advantage

  6. The Market: Exaggerated Woes

    Endo Pharmaceuticals ENDP announced July 11 that it no longer expects to file a new drug application for its ketoprofen pain-relief patch by the first half of 2008 because of lackluster Phase III trial results. The drug candidate failed to show statistically significant results for pain relief in ...

  7. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

  8. Health Care: 3 Picks in a More Expensive Sector

    Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.

  9. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

  10. Our Outlook for the Credit Markets

    The corporate bond market will probably struggle to return much above break-even in 2014.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.